Trials / Withdrawn
WithdrawnNCT04200989
Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy
Intra-lymphatic Immunotherapy for the Management of Peanut Allergy
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Scripps Health · Academic / Other
- Sex
- All
- Age
- 15 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.
Detailed description
Eligible subject undergo a baseline blinded oral peanut challenge. Then the peanut ILIT as described above. Pretreatment with antihistamines, leukotriene modifier and albuterol before each treatment. Following the three ILIT peanut injections a repeat blinded oral peanut challenge is performed. Blood is drawn at each of the 5 study visits for a variety of tests trying to elucidate the mechanism(s) of the induction of tolerance to peanut.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peanut allergen | Intralymphatic immunotherapy injections. |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2019-12-16
- Last updated
- 2022-11-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04200989. Inclusion in this directory is not an endorsement.